abiraterone acetate   Click here for help

GtoPdb Ligand ID: 9288

Synonyms: Yonsa® | Zytiga®
Approved drug
abiraterone acetate is an approved drug (EMA & FDA (2011))
Compound class: Synthetic organic
Comment: Abiraterone acetate is an ester prodrug of the steroidal drug abiraterone, which acts as an androgen synthesis inhibitor by inhibiting steroid 17alpha-monooxygenase.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 39.19
Molecular weight 391.25
XLogP 6.28
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CC(=O)OC1CCC2(C(=CCC3C2CCC2(C3CC=C2c2cccnc2)C)C1)C
Isomeric SMILES CC(=O)O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC=C2c2cccnc2)C)C1)C
InChI InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
No information available.
Summary of Clinical Use Click here for help
Abiraterone acetate is used to treat refractory prostate cancer in combination with prednisone or prednisolone. In May 2018, the US FDA approved a novel, ultramicrosized formulation of abiraterone acetate (Yonsa®) for the treatment of metastatic castration-resistant prostate cancer, that is to be used in combination with methylprednisolone.
External links Click here for help